Latest Breaking News On - Vigil neuroscience inc - Page 21 : comparemela.com

Bionomics appoints Spyridon Spyros Papapetropoulos as President and Chief Executive Officer

Bionomics appoints Spyridon Spyros Papapetropoulos as President and Chief Executive Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSouth australiaSpyridon spyros papapetropoulosNdas blasConnor bernsteinviceHead of development at acadia pharmaceuticals incSchool of medicineTeva pharmaceuticals incDirectors of the companyResearch developmentBionomics limited nasdaqBiogen incMerck co incPfizer incBionomics ltdBionomics limitedbionomics limited

Vigil Neuroscience Appoints David Gray, Ph D , as Chief Scientific Officer and Announces Changes to Executive Team

15.12.2022 - – Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases – – Dr. Spyros Papapetropoulos to depart Vigil to pursue a Chief Executive Officer opportunity – CAMBRIDGE, . Seite 1

United kingdomDavid grayIvana magovSpyros papapetropoulosScripps research instituteChemistry at cerevel therapeutics holdings incVigil neuroscience incCompany onPfizer incUniversity of minnesotaInscopix incChief scientific officerChief medical officerChief executive officerScientific advisoryChief scientific

Vigil Neuroscience (VIGL) Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP

Vigil Neuroscience (VIGL) Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ivana magovSpyros papapetropoulosVigil neuroscience incChief executive officerChief medical officer

VIGIL NEUROSCIENCE, INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

Item 2.02 Results of Operations and Financial Condition On November 10, 2022, Vigil Neuroscience, Inc. issued a press release announcing its financial results for the three and nine months ended. | November 10, 2022

Securities exchangeVigil neuroscience incPress releaseSecurities exchange actSecurities actExchange actPage interactive data fileEdgar onlineVigil neuroscienceNc stock exchangePress releaseOnths vigl us92673k1088

Vigil Neuroscience (VIGL) Reports Interim Topline Results from Phase 1 Trial of VGL101

Vigil Neuroscience (VIGL) Reports Interim Topline Results from Phase 1 Trial of VGL101
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ivana magovSpyros papapetropoulosExchange commissionVigil neuroscience incWall streetChief executive officerChief medical officerVigil neuroscienceAnnual reportQuarterly report